Type of Assessment:
Using an artificial intelligence tool to improve the recognition of pseudoprogression in pleural mesothelioma patients treated with immunotherapy: a case series
Translational Lung Cancer Research 2026 August 31 [Link] Illaa Smesseim, Kalina Chupetlovska, Valerio Pugliese, Jacobus A Burgers, Kevin B W Groot Lipman Abstract Background: Pseudoprogression, defined as initial radiological tumor growth followed by treatment response, can complicate treatment response assessment in patients receiving immunotherapy. In pleural mesothelioma (PM) patients treated with immunotherapy reliable identification of…
Read MoreHyperthermic intrathoracic chemotherapy after cytoreductive surgery in malignant pleural mesothelioma: a single-center retrospective cohort study suggesting increased morbidity without survival benefit
Journal of Thoracic Disease 2026 August 31 [Link] Natalie Baldes, Fabian Doerr, Konstantinos Grapatsas, Balazs Hegedüs, Martin Metzenmacher, Dirk Theegarten, Christian Taube, Martin Schuler, Servet Bölükbas Abstract Background: In the multimodal treatment of pleural mesothelioma (PM), hyperthermic intrathoracic chemotherapy (HITOC) has been investigated as an adjunct to cytoreductive surgery (CRS) to potentially improve local tumor…
Read MoreMesenteric Peritonectomy as the Seventh Peritonectomy Technique in Cytoreductive Surgery for Peritoneal Surface Malignancies: A Propensity Score-Matched Analysis
Annals of Surgical Oncology 2026 September 11 [Link] Francesca Laura Nava, Tommaso Cavalleri, Dario Baratti, Marcello Guaglio, Shigeki Kusamura, Marcello Deraco Abstract Background: Mesenteric involvement represents a major challenge in cytoreductive surgery (CRS) for peritoneal surface malignancies, historically regarded as a relative contraindication to complete cytoreduction. Mesenteric peritonectomy (MP), first described by Deraco et al.…
Read MoreLong-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
Lung Cancer 2026 November [Link] Jean-Baptiste Assié, Laurent Greillier, Aurelien Gobert, Lionel Falchero, Lise Thibonnier, Matthieu Chasseray, Christine Raynaud, Hugo Picchi, Thierry Chatellier, Romain Corre, Olivier Molinier, Alain Bakebe, Charles Naltet, Fleur-Marie Quillot, Laurene Gavoille, Thomas Pierret, Jean-Marc Dot, Marie Wislez, Marielle Sabatini, Marie Tiercin, Gerard Zalcman, Ophelie Cassuto, Remy Largillier, Anne Madroszyk, Nadia Munsch,…
Read MorePre-treatment Tumor Volume Growth Rate and Baseline Volume Measured by an Artificial Intelligence Program Predict Overall Survival in Patients With Pleural Mesothelioma Undergoing Deferred Systemic Therapy
JTO Clinical and Research Reports 2026 June 30 [Link] Illaa Smesseim, Valerio Pugliese, Jacobus Burgers, Kevin Groot Lipman Abstract Introduction: The optimal timing of systemic therapy in pleural mesothelioma remains debated, particularly for asymptomatic patients with a limited disease burden. Prior studies suggest that deferred treatment may not compromise overall survival (OS) in selected patients.…
Read MoreMulti-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy
Frontiers in Oncology 2026 August 13 [Link] Hongmei Li, Kunzhong Zhou, Ruiting Xu, Weifang Wang, Tingting Song, Yonghong Zhou, Jing Ren, Zhiyong Wang, Yiteng Liang, Yilin Chen, Saurav Poudel, Junxuan Yu, Rui Lin, Ke Yin, Shengjie Yang, Li Zhuang Abstract Malignant pleural mesothelioma (MPM) exhibits substantial molecular and cell-state heterogeneity, together with marked spatial variation…
Read MoreThonzonium bromide suppresses malignant phenotypes of pleural mesothelioma cells in association with reduced KAP1 Ser473 phosphorylation
Tissue & Cell 2026 August 22 [Link] Dan Song, Jintao He, Qianwen Du, Shaoyang Huang, Wenbing Huang, Zhengliang Li, Zifeng Ruan, Xingguo Liu, Jing Zhang, Wei Xiong Abstract Objective: Pleural mesothelioma (PM) is an aggressive thoracic malignancy with limited therapeutic options. This study investigated the biological role of KAP1 in PM and explored the relationship…
Read MoreAsbestos mineral fibre exposure significantly affects volatile organic compound profiles of mesothelial cell lines in vitro
Scientific Reports 2026 August 29 [Link] Sam Bonsall, Theo Issitt, Nick Peake, Mari Herigstad, Jason Webber, Sarah Haywood-Small Abstract Malignant mesothelioma (MM) is a rare cancer caused by exposure to asbestos, this condition continues to represent a significant diagnostic and therapeutic challenge. Due to the long disease latency, non-invasive diagnostic modalities such as breath analysis…
Read MorePrognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis
Cancers 2026 August 11 [Link] Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz Abstract Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO…
Read MoreSex-Specific Patterns of Asbestos Exposure and Prognostic Biomarkers in Surgically Treated Pleural Mesothelioma: A Retrospective Cohort Study
Cancers 2026 August 14 [Link] Nicolas Pinzon, Shubham Gulati, Andrew Del Re, Emanuela Taioli, Raja Flores, Andrea S Wolf, Stephanie Tuminello Abstract Background/objectives: Sex-based differences in asbestos exposure and tumor biology in pleural mesothelioma (PM) remain incompletely characterized. As an expert tertiary center, we sought to systematically characterize asbestos exposure by sex and assess biomarker…
Read More
Skip to content